UFT
Executive Summary
Bristol does "not agree with FDA's interpretation of the study results" for uracil/tegafur combination oncologic agent, Worldwide Medicines Group President Richard Lane says. Bristol received a "non-approvable" letter from FDA for UFT March 23, after it resubmitted the NDA (1"The Pink Sheet" April 2, In Brief). Bristol is "still reviewing our options"